Hansoh Pharmaceutical Group Company Limited (FRA:3KY)

Market Cap	18.10B
Revenue (ttm)	1.62B
Net Income (ttm)	578.53M
Shares Out	n/a
EPS (ttm)	0.10
PE Ratio	31.28
Forward PE	32.73
Dividend	0.04 (1.41%)
Ex-Dividend Date	Sep 20, 2024

Volume	n/a
Average Volume	4,201
Open	2.860
Previous Close	3.060
Day's Range	2.840 - 2.860
52-Week Range	1.800 - 3.060
Beta	n/a
RSI	60.99
Earnings Date	May 27, 2025

About FRA:3KY

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 8,989
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3KY

Financial Performance

In 2024, FRA:3KY's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY